Copy to clipboard 
Amplitude Surgical reported FY 2Q21 orthopedic revenue of €24.3 (USD $29.7) million, -16.1% vs. FY 2Q20. The company’s fiscal second quarter corresponds with the calendar fourth quarter, and therefore suffered the impact of COVID’s winter surge. Amplitude leadership pointed to Brazil, Germany and Australia as markets hit particularly hard by operating room restrictions. However, the company’s Novastep foot and ankle line remains a bright spot. Sales from Novastep now account for 13% of Amplitude’s total revenue, driven by 42% growth in the U.S.
“Amplitude Surgical’s activity was impacted, in the second quarter, by the deterioration in the public health situation associated with COVID-19 on the majority of its markets and by the adoption of restrictions on access to operating rooms. Despite the COVID-19 impact, the Group is in a solid financial position and intends to seize any external growth opportunities by looking into openings to acquire rival companies or agent.” – Olivier Jallabert, Amplitude Surgical CEO
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 2Q21 | 2Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $24.3 | $30.2 | ($5.8) | (19.3%) |
| Knees | $14.2 | $17.7 | ($3.4) | (19.5%) |
| Hips | $10.1 | $12.5 | ($2.4) | (19.1%) |
| Trauma | $4.5 | $3.5 | $1.0 | 30.2% |
| Sports Medicine | $0.5 | $1.1 | ($0.5) | (49.7%) |
| Orthobiologics | $0.3 | $0.7 | ($0.4) | (58.1%) |
| Total | $29.7 | $35.4 | ($5.7) | (16.1%) |
| 1H21 | 1H20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $46.5 | $51.9 | ($5.5) | (10.5%) |
| Knees | $27.1 | $30.6 | ($3.4) | (11.1%) |
| Hips | $19.3 | $21.4 | ($2.1) | (9.6%) |
| Trauma | $7.4 | $5.9 | $1.6 | 27.1% |
| Sports Medicine | $1.3 | $1.8 | ($0.5) | (28.8%) |
| Orthobiologics | $0.8 | $1.2 | ($0.4) | (32.3%) |
| Total | $56.0 | $60.8 | ($4.8) | (7.9%) |
Geographic Sales
| 2Q21 | 2Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $18.9 | $22.3 | ($3.5) | (15.5%) |
| International | $10.8 | $13.0 | ($2.2) | (17.1%) |
| Subsidiaries | $8.5 | $9.2 | ($0.7) | (8.1%) |
| Distributors | $2.3 | $3.8 | ($1.5) | (38.7%) |
| Total | $29.7 | $35.4 | ($5.7) | (16.1%) |
| 1H21 | 1H20 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $36.1 | $37.1 | ($1.0) | (2.6%) |
| International | $19.9 | $23.7 | ($3.8) | (16.1%) |
| Subsidiaries | $15.2 | $17.5 | ($2.3) | (13.3%) |
| Distributors | $4.7 | $6.2 | ($1.5) | (24.2%) |
| Total | $56.0 | $60.8 | ($4.8) | (7.9%) |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Amplitude Surgical reported FY 2Q21 orthopedic revenue of €24.3 (USD $29.7) million, -16.1% vs. FY 2Q20. The company’s fiscal second quarter corresponds with the calendar fourth quarter, and therefore suffered the impact of COVID’s winter surge. Amplitude leadership pointed to Brazil, Germany and Australia as markets hit particularly hard by...
Amplitude Surgical reported FY 2Q21 orthopedic revenue of €24.3 (USD $29.7) million, -16.1% vs. FY 2Q20. The company’s fiscal second quarter corresponds with the calendar fourth quarter, and therefore suffered the impact of COVID’s winter surge. Amplitude leadership pointed to Brazil, Germany and Australia as markets hit particularly hard by operating room restrictions. However, the company’s Novastep foot and ankle line remains a bright spot. Sales from Novastep now account for 13% of Amplitude’s total revenue, driven by 42% growth in the U.S.
“Amplitude Surgical’s activity was impacted, in the second quarter, by the deterioration in the public health situation associated with COVID-19 on the majority of its markets and by the adoption of restrictions on access to operating rooms. Despite the COVID-19 impact, the Group is in a solid financial position and intends to seize any external growth opportunities by looking into openings to acquire rival companies or agent.” – Olivier Jallabert, Amplitude Surgical CEO
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 2Q21 | 2Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $24.3 | $30.2 | ($5.8) | (19.3%) |
| Knees | $14.2 | $17.7 | ($3.4) | (19.5%) |
| Hips | $10.1 | $12.5 | ($2.4) | (19.1%) |
| Trauma | $4.5 | $3.5 | $1.0 | 30.2% |
| Sports Medicine | $0.5 | $1.1 | ($0.5) | (49.7%) |
| Orthobiologics | $0.3 | $0.7 | ($0.4) | (58.1%) |
| Total | $29.7 | $35.4 | ($5.7) | (16.1%) |
| 1H21 | 1H20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $46.5 | $51.9 | ($5.5) | (10.5%) |
| Knees | $27.1 | $30.6 | ($3.4) | (11.1%) |
| Hips | $19.3 | $21.4 | ($2.1) | (9.6%) |
| Trauma | $7.4 | $5.9 | $1.6 | 27.1% |
| Sports Medicine | $1.3 | $1.8 | ($0.5) | (28.8%) |
| Orthobiologics | $0.8 | $1.2 | ($0.4) | (32.3%) |
| Total | $56.0 | $60.8 | ($4.8) | (7.9%) |
Geographic Sales
| 2Q21 | 2Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $18.9 | $22.3 | ($3.5) | (15.5%) |
| International | $10.8 | $13.0 | ($2.2) | (17.1%) |
| Subsidiaries | $8.5 | $9.2 | ($0.7) | (8.1%) |
| Distributors | $2.3 | $3.8 | ($1.5) | (38.7%) |
| Total | $29.7 | $35.4 | ($5.7) | (16.1%) |
| 1H21 | 1H20 | $ Chg | % Chg | |
|---|---|---|---|---|
| France | $36.1 | $37.1 | ($1.0) | (2.6%) |
| International | $19.9 | $23.7 | ($3.8) | (16.1%) |
| Subsidiaries | $15.2 | $17.5 | ($2.3) | (13.3%) |
| Distributors | $4.7 | $6.2 | ($1.5) | (24.2%) |
| Total | $56.0 | $60.8 | ($4.8) | (7.9%) |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
